PET Imaging of LAG-3 Expression

Status Recruiting

Clinical Trial Summary

To evaluate the potential usefulness of 68Ga-DOTA-hLAG-3 positron emission tomography/computed tomography (PET/CT) for the evaluation of LAG-3 expression in primary and/or metastatic tumors, compared with histopathological results.

Clinical Trial Description

Participants with cancer underwent 68Ga-DOTA-hLAG-3 PET/CT for an initial assessment. Tumor uptake was quantified by the maximum standard uptake value (SUVmax) and mean SUV (SUVmean). In addition, the LAG-3 expression of lesions was confirmed by histopathological analyzing. The quantitative parameters of 68Ga-DOTA-hLAG-3 PET/CT were compared with histopathological result to evaluate the diagnostic efficacy. ;

Study Design

Related Conditions & MeSH terms

Tumor, Solid

Clinical Trial Details

NCT number	NCT05346276
Study type	Interventional
Source	The First Affiliated Hospital of Xiamen University
Contact	Long Sun, PhD
Phone	86 0592-2137077
Email	13178352662@163.com
Status	Recruiting
Phase	N/A
Start date	April 6, 2022
Completion date	May 1, 2024

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05094804` - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents	Phase 1/Phase 2
Recruiting	`NCT05637034` - 68Ga-DOTA-F2 PET/CT in Patients With Various Types of Cancer	N/A
Terminated	`NCT04095091` - Real-time Tumor Localization and Guidance for Radiotherapy Using Ultrasound (US) and Magnetic Resonance (MR)
Recruiting	`NCT05378425` - A Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR, CD155), as Monotherapy and Combined With Pembrolizumab	Phase 1
Not yet recruiting	`NCT04723810` - TumorGlow Intraoperative Molecular Imaging (IMI)	Phase 1/Phase 2
Recruiting	`NCT06116032` - Immune Profiling for Cancer Immunotherapy Response
Recruiting	`NCT06090266` - A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents	Phase 1/Phase 2
Recruiting	`NCT04416165` - Comparison of FDG and FAPI in Patients With Various Types of Cancer	N/A
Recruiting	`NCT05620134` - Study of JK08 in Patients With Unresectable Locally Advanced or Metastatic Cancer	Phase 1/Phase 2
Recruiting	`NCT04750772` - Positron Nuclide Labeled DOTA-FAPI PET Study in Colocrectal Cancer	N/A
Recruiting	`NCT06022029` - A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.	Phase 1
Terminated	`NCT01358331` - A Study of the Safety, Tolerability, and Efficacy of MK-8353 in Participants With Advanced Solid Tumors (MK-8353-001)	Phase 1
Recruiting	`NCT06175221` - Autologous TLPO Vaccine Basket	Phase 2
Recruiting	`NCT05661461` - Dose-escalation Study to Assess Safety and Pharmacokinetics of Nab-Sirolimus in Patients With Locally Advanced or Metastatic Solid Tumors and Moderate Liver Impairment	Phase 1
Active, not recruiting	`NCT04196530` - BDB001-102: Open Label Dose Escalation of BDB001 in Combination w Atezolizumab	Phase 1
Not yet recruiting	`NCT03731390` - GR1405 Injection in Patients With Advanced Solid Tumor or Lymphoma	Phase 1
Active, not recruiting	`NCT03491631` - Phase I Study of SHR9146 + SHR-1210 +/- Apatinib in Patients With Advanced Solid Tumors	Phase 1
Recruiting	`NCT06193902` - LEU01101: Safety and Preliminary Efficacy of LEU011 in Solid Tumours.	Phase 1/Phase 2
Active, not recruiting	`NCT04528836` - First-in-Human Study of the SHP2 Inhibitor BBP-398 in Patients With Advanced Solid Tumors	Phase 1
Recruiting	`NCT05221320` - Trial of Ulixertinib in Combination With Hydroxychloroquine in Patients With Advanced Gastrointestinal (GI) Malignancies	Phase 2